Hemo Organic Peer Comparison

BSE: 524590

₹20.99

₹-0.86 (-3.94%)

As on 02-Nov-2026IST

Market cap

₹14 Cr

Revenue (TTM)

₹2 Cr

P/E Ratio

--

P/B Ratio

4.4

Div. Yield

0 %

Edit

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Market cap (₹ Cr)	14	32	42,042	32,864	33,015
Revenue (₹ Cr)	2	45	10,234	9,779	3,751
Net Profit (₹ Cr)	-0.73	0.56	1,092.67	-270.51	405.00
Net Margin (%)	-30.96	1.22	10.67	-2.71	10.48
RoE (%)	-43.14	3.26	21.65	-2.55	7.91
Price to Earnings	--	57.67	38.45	--	80.52
Price-To-Book	4.43	1.84	7.87	4.03	6.40

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Operating Revenue	0.93	30.46	9,203.54	8,869.08	3,373.00
Total Income	0.93	30.77	9,335.01	9,111.51	3,510.00
Total Expenditure	1.43	29.82	7,457.80	7,976.59	2,747.00
EBITDA	-0.50	0.64	1,745.74	892.49	626.00
Depreciation	0.00	0.23	415.05	831.24	227.00
EBIT	-0.50	0.40	1,330.70	61.25	399.00
Interest	0.00	0.18	143.67	340.80	213.00
Other Income	0.00	0.31	131.47	242.43	137.00
Exceptional Items	--	--	-31.35	-196.14	-85.00
Profit before Tax	-0.50	0.53	1,287.14	-176.06	238.00
Provision for Tax	0.28	0.13	345.87	149.88	39.00
Profit after Tax	-0.78	0.40	941.27	-325.94	199.00

Liabilities (₹ Cr)

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Shareholder's Funds	0.13	16.54	4,950.03	8,162.62	4,940.00
Minority Interest	--	--	26.64	--	341.00
Non-Current Liabilities	2.74	-1.08	584.19	4,529.41	1,235.00
Current Liabilities	1.59	3.43	3,912.24	4,874.74	1,622.00
Total Liabilities	4.46	20.05	9,514.48	17,723.32	8,578.00

Assets (₹ Cr)

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Non-Current Assets	0.00	6.22	3,861.01	10,258.66	5,441.00
Current Assets	4.46	12.67	5,612.10	7,308.11	2,606.00
Total Assets	4.46	20.05	9,514.48	17,723.32	8,578.00
Total Debt*	2.74	2.65	1,204.08	5,495.48	2,125.00
Net Current Assets	2.87	9.24	1,699.86	2,433.37	984.00
Contingent Liabilities	--	--	258.92	95.72	768.26

Cashflow (₹ Cr)

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Cash From Operating Activities	-1.46	-4.34	943.55	1,652.60	390.00
Cash Flow from Investing Activities	-0.86	-0.44	-1,193.06	-826.03	-241.00
Cash from Financing Activities	2.32	2.50	343.43	-38.98	-54.00
Net Cash Inflow / Outflow	0.00	-2.27	93.92	787.59	95.00

Ratios

Profitability Ratios

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
ROCE (%)	-23.54	4.01	25.25	1.24	6.79
ROE (%)	0.00	2.52	20.09	-4.04	4.29
ROA (%)	-16.99	2.26	10.70	-1.98	2.53
EBIT Margin (%)	-53.18	3.10	20.40	12.80	22.62
Net Margin (%)	-83.58	1.29	10.08	-3.58	5.67
Cash Profit Margin (%)	-83.69	2.07	14.44	4.80	10.98

Growth Ratios

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Revenue Growth (%)	-61.52	142.65	16.56	-3.08	11.99
EBIT Growth (%)	-1,851.77	116.15	21.77	-28.15	67.69
Net Profit Growth (%)	-574.74	161.64	33.05	-457.66	449.12
EPS Growth (%)	-574.73	148.44	35.59	-456.91	553.20
Book Value Growth (%)	-513.60	11.39	11.36	0.33	13.47

Valuation Ratios

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Price / Earnings	0.00	97.44	32.73	0.00	89.54
Price / Book Value	-4.36	2.33	6.13	2.24	3.87
Dividend Yield (%)	0.00	0.00	0.23	0.00	0.00
EV/EBITDA	-13.73	43.15	16.68	19.72	27.45
Market Cap (₹ Cr)	4.06	38.60	30,257.56	18,108.89	19,071.62

Solvency Ratios

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Debt to Equity	-2.95	0.16	0.24	0.68	0.43
Short term debt to equity ratio	--	0.16	0.16	0.09	0.09
Current Ratio	2.81	3.69	1.43	1.50	1.61
Quick Ratio	2.49	2.35	0.82	0.87	1.06
Interest Coverage	-133.68	3.87	9.96	0.48	2.12

Operating Efficiency Ratios

	Hemo Organic	Panjon	Emcure Pharmaceuticals	Piramal Pharma	Wockhardt
Debtors to sales (%)	257.12	10.71	27.84	24.33	17.43
Asset Turnover	0.20	1.74	1.07	0.64	0.49
Receivable days	963.79	30.38	88.68	78.20	58.75
Inventory Days	378.08	50.09	84.11	93.30	75.82
Payable days	1,020.02	3.05	176.65	226.14	186.21
Cash Conversion Cycle	321.86	77.42	-3.86	-54.64	-51.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly